Faculty: B. Douglas Smith, MD
Last Modified: October 21, 2012
Chronic myeloid leukemia (CML) is a myeloproliferative disorder of the blood stem cells that accounts for approximately 15% of all adult leukemias. Recent changes to standard therapy, combined with the development of novel CML agents, have led to challenges with regard to escalation and transition of therapy and management of treatment-related side effects. This continuing education activity will improve the ability of oncologists and other clinicians to treat and manage CML through application of contemporary CML guidelines and utilization of novel CML therapies.
Dec 7, 2010 - Nilotinib may improve survival in some chronic myeloid leukemia (CML) patients, and patients with various types of CML respond well to ponatinib, according to research being presented at the annual meeting of the American Society of Hematology, held from Dec. 4 to 7 in Orlando, Fla. Other studies being presented outline the optimal use of imatinib, address how a new gene target functions for several myeloid malignancies, highlight a tool for predicting acute myeloid leukemia outcomes, and address the use of mitoxantrone in acute lymphoblastic leukemia.
May 9, 2013